# MMJ International Holdings

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/mmj-international-holdings
Canonical HTML page: https://getyourbrief.com/entity/mmj-international-holdings

## Timeline

- **2026-08-17**: Post-Hearing Briefs Due — Parties submit final briefs to Administrative Law Judge Derek C. Julius, summarizing their arguments on the evidentiary record and legal standards. The recommendation on rescheduling is expected to follow shortly thereafter.
- **2026-07-08**: Rescheduling Hearing Testimony — Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation.
- **2026-07**: ALJ Hearing on Marijuana Rescheduling — A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence.
- **2026-06**: DEA Excludes MMJ from Rescheduling Hearing — The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law.
- **2024**: DEA Scientific Data Review Published — Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use.

## Recent coverage (7 stories, network-wide)

### DEA's 5-Part Medical-Use Test Under Fire as Marijuana Rescheduling Hearing Heads to August 17 Briefs
2026-08-10 03:18:11 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2

ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard.
Full story: https://getlegalbrief.com/story/dea-marijuana-rescheduling-legal-tensions

### DEA's Own Expert: Marijuana Fails 3 of 5 Medical Use Factors—Order at Risk
2026-07-27 07:23:59 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 2

DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking.
Full story: https://getlegalbrief.com/story/dea-expert-marijuana-fails-medical-use-test-legal-challenge

### DEA Excluded MMJ, Only FDA-Pathway Developer with $10M in Research, from Rescheduling Hearing
2026-07-13 06:01:24 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2

MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule.
Full story: https://getlegalbrief.com/story/dea-excludes-mmj-fda-cannabinoid-rescheduling-hearing

### MSO Stock Catalyst? $2.2B Annual Tax Release at Stake in Marijuana Rescheduling Case
2026-07-12 01:19:12 · Sector: finance · Sentiment: Positive · Impact: 9/10 · Sources: 1

Investors are watching the D.C. Circuit case closely as MMJ International Holdings claims marijuana rescheduling would deliver over $2 billion in annual tax savings to multi-state operators, potentially boosting profitability and stock prices.
Full story: https://getfinancebrief.com/story/mso-tax-savings-rescheduling-case

### Cannabis Startups Could Pocket $2.2B in Tax Savings If Rescheduling Holds, Advocate Warns
2026-07-12 01:18:06 · Sector: startups · Sentiment: Positive · Impact: 9/10 · Sources: 1

MMJ International Holdings' latest filing reveals that up to $2.24 billion in annual 280E tax overpayments could be reversed, plus $1.6B in accrued unpaid taxes forgiven—a sum that would transform balance sheets for cash-strapped cannabis startups.
Full story: https://getstartupbrief.com/story/cannabis-startups-280e-tax-windfall

### Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says
2026-07-12 01:17:30 · Sector: bio · Sentiment: Positive · Impact: 9/10 · Sources: 1

The potential elimination of 280E taxes on cannabis businesses could inject over $2 billion annually into the biotech sector, accelerating cannabinoid drug development. MMJ International Holdings' latest press release quantifies the stakes.
Full story: https://getbiobrief.com/story/cannabis-rescheduling-biotech-tax-savings

### Medical Cannabis Could See $2.2B Annual Tax Relief from Rescheduling, Challenger Claims
2026-07-12 01:16:54 · Sector: health · Sentiment: Positive · Impact: 9/10 · Sources: 1

MMJ International Holdings says moving cannabis to Schedule III would wipe out $2.24B in annual excess 280E taxes, unlocking capital for patient programs and medical research. The legal dispute spotlights the massive healthcare economic stakes of drug scheduling.
Full story: https://gethealthbrief.com/story/medical-cannabis-tax-relief-rescheduling

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.